Article info
PDFCorrespondence response
Response to: ‘COVID-19 in patients with rheumatic diseases: what is the real mortality risk?’ by Marques et al
- Correspondence to Dr Zachary Scott Wallace, Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA; zswallace{at}partners.org
Citation
Response to: ‘COVID-19 in patients with rheumatic diseases: what is the real mortality risk?’ by Marques et al
Publication history
- Received June 26, 2020
- Accepted June 29, 2020
- First published July 13, 2020.
Online issue publication
July 12, 2022
Article Versions
- Previous version (13 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage